Hims & Hers Health, Inc. (NYSE:HIMS) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Hims & Hers Health, Inc. (NYSE:HIMS) have been given a consensus recommendation of “Moderate Buy” by the sixteen analysts that are presently covering the company, Marketbeat reports. Seven investment analysts have rated the stock with a hold rating and nine have issued a buy rating on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $17.00.

Several equities analysts have recently commented on HIMS shares. Deutsche Bank Aktiengesellschaft upped their target price on Hims & Hers Health from $14.00 to $16.00 and gave the company a “hold” rating in a report on Tuesday, May 7th. Bank of America upped their target price on Hims & Hers Health from $22.00 to $26.00 and gave the company a “buy” rating in a report on Thursday, June 13th. Seaport Res Ptn reaffirmed a “buy” rating on shares of Hims & Hers Health in a report on Friday, April 26th. Canaccord Genuity Group upped their target price on Hims & Hers Health from $20.00 to $24.00 and gave the company a “buy” rating in a report on Wednesday, May 22nd. Finally, Canaccord Genuity Group assumed coverage on Hims & Hers Health in a report on Wednesday, April 10th. They set a “buy” rating and a $20.00 target price for the company.

Hims & Hers Health Stock Up 0.7 %

Shares of NYSE HIMS opened at $20.16 on Monday. The stock’s 50 day moving average price is $17.59 and its two-hundred day moving average price is $13.48. Hims & Hers Health has a 52-week low of $5.65 and a 52-week high of $25.74. The stock has a market capitalization of $4.33 billion, a P/E ratio of -2,016.00 and a beta of 1.08.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, May 6th. The company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.03. Hims & Hers Health had a negative return on equity of 0.70% and a negative net margin of 0.24%. The firm had revenue of $278.20 million for the quarter, compared to analysts’ expectations of $270.37 million. During the same quarter in the prior year, the firm posted ($0.05) earnings per share. Hims & Hers Health’s revenue for the quarter was up 45.8% compared to the same quarter last year. On average, analysts anticipate that Hims & Hers Health will post 0.19 EPS for the current year.

Insider Activity

In other news, insider Soleil Boughton sold 2,502 shares of the stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $17.33, for a total transaction of $43,359.66. Following the completion of the sale, the insider now owns 156,855 shares in the company, valued at approximately $2,718,297.15. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, insider Soleil Boughton sold 2,502 shares of the stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $17.33, for a total value of $43,359.66. Following the completion of the sale, the insider now owns 156,855 shares in the company, valued at $2,718,297.15. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Oluyemi Okupe sold 11,546 shares of the company’s stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $22.21, for a total transaction of $256,436.66. Following the completion of the transaction, the chief financial officer now directly owns 177,449 shares in the company, valued at $3,941,142.29. The disclosure for this sale can be found here. In the last 90 days, insiders sold 962,791 shares of company stock worth $16,930,725. Insiders own 17.71% of the company’s stock.

Hedge Funds Weigh In On Hims & Hers Health

Hedge funds have recently modified their holdings of the stock. Victory Capital Management Inc. increased its stake in shares of Hims & Hers Health by 23.0% in the fourth quarter. Victory Capital Management Inc. now owns 18,348 shares of the company’s stock worth $163,000 after acquiring an additional 3,429 shares during the last quarter. Graham Capital Management L.P. increased its stake in shares of Hims & Hers Health by 39.4% in the third quarter. Graham Capital Management L.P. now owns 340,338 shares of the company’s stock worth $2,141,000 after acquiring an additional 96,277 shares during the last quarter. Forerunner Ventures Management LLC acquired a new position in shares of Hims & Hers Health in the fourth quarter worth $86,836,000. Swiss National Bank increased its position in Hims & Hers Health by 9.2% during the third quarter. Swiss National Bank now owns 309,200 shares of the company’s stock worth $1,945,000 after buying an additional 26,100 shares during the last quarter. Finally, Vanguard Group Inc. increased its position in Hims & Hers Health by 3.1% during the third quarter. Vanguard Group Inc. now owns 14,126,744 shares of the company’s stock worth $88,857,000 after buying an additional 428,671 shares during the last quarter. 63.52% of the stock is owned by institutional investors and hedge funds.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.